Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aspira Pathlab & DiagnosticsBOM:540788 -1.97%51 Days Inventory is 39.83 as of Mar. 2026, which is 10% below its 10-year median of 44.35. GuruFocus rates BOM:540788 with a GF Score™ of 51/100 and a GF Value™ of ₹70.73 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 178 Medical Diagnostics & Research companies, Aspira Pathlab & Diagnostics ranks better than 70.22% on this metric.
The historical rank and industry rank for Aspira Pathlab & Diagnostics's Days Inventory or its related term are showing as below:
BOM:540788'
s Days Inventory Range Over the Past 10 Years
Min: 24.21 Med: 44.35 Max: 273.58
Current: 38.88
During the past 13 years, Aspira Pathlab & Diagnostics's highest Days Inventory was 273.58. The lowest was 24.21. And the median was 44.35.
BOM:540788's Days Inventory is ranked better than 70.22% of 178
companies
in the Medical Diagnostics & Research industry
Industry Median: 66.965
vs BOM:540788: 38.88
Inventory Turnover measures how fast the company turns over its inventory within a year.
Aspira Pathlab & Diagnostics's Inventory Turnover for the
three
months ended in Mar. 2026 was 2.29.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Aspira Pathlab & Diagnostics's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.11.
Aspira Pathlab & Diagnostics (BOM:540788) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Aspira Pathlab & Diagnostics's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Aspira Pathlab & Diagnostics's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Aspira Pathlab & Diagnostics Days Inventory Related Terms
Aspira Pathlab & Diagnostics Days Inventory Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:540788 vs TMO, DHR, IDXX: Days Inventory Comparison
For the Diagnostics & Research subindustry, Aspira Pathlab & Diagnostics's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aspira Pathlab & Diagnostics Days Inventory vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Aspira Pathlab & Diagnostics's Days Inventory distribution charts can be found below:
* The bar in red indicates where Aspira Pathlab & Diagnostics's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aspira Pathlab & Diagnostics (BOM:540788) has a Days Inventory of 39.83 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Aspira Pathlab & Diagnostics and its competitors. This is 10% below median its historical median of 44.35. Over the past decade, Aspira Pathlab & Diagnostics' Days Inventory has ranged from 24.21 to 273.58. According to the industry distribution chart, Aspira Pathlab & Diagnostics ranks #53 out of 178 companies in the Medical Diagnostics & Research industry, placing it in the top 29.8%.
Is Aspira Pathlab & Diagnostics' Days Inventory too high?
Aspira Pathlab & Diagnostics' current Days Inventory of 39.83 is 10% below median its 10-year median of 44.35. Over the past 10 years, this metric has ranged from a low of 24.21 to a high of 273.58. The Medical Diagnostics & Research industry median Days Inventory is 66.97. Aspira Pathlab & Diagnostics' value of 39.83 is 40.5% below this industry median. Based on the distribution chart, Aspira Pathlab & Diagnostics ranks #53 out of 178 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Aspira Pathlab & Diagnostics has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aspira Pathlab & Diagnostics' Days Inventory compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Aspira Pathlab & Diagnostics ranks #53 out of 178 companies for Days Inventory. This puts Aspira Pathlab & Diagnostics in the upper half of its industry. The industry median Days Inventory is 66.97. Aspira Pathlab & Diagnostics' value of 39.83 is 40.5% below this benchmark. Historically, Aspira Pathlab & Diagnostics' own Days Inventory has ranged from 24.21 to 273.58 over the past decade. While the company's 10-year median is 44.35 vs. the industry median of 66.97, Aspira Pathlab & Diagnostics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Medical Diagnostics & Research company?
The median Days Inventory among Medical Diagnostics & Research companies is 66.97, based on 178 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aspira Pathlab & Diagnostics's current Days Inventory of 39.83 is 40.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Aspira Pathlab & Diagnostics and its competitors. For the Medical Diagnostics & Research industry, the median Days Inventory is 66.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aspira Pathlab & Diagnostics's current Days Inventory is 39.83, which is 10% below median its own 10-year median of 44.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aspira Pathlab & Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Aspira Pathlab & Diagnostics (BOM:540788) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹70.73, compared to a current price of ₹106.90 — trading 51.1% above its estimated fair value. The current Days Inventory is 39.83, which is 10% below median its 10-year median of 44.35 and 40.5% below the Medical Diagnostics & Research industry median of 66.97. Aspira Pathlab & Diagnostics' overall GF Score™ is 51/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Aspira Pathlab & Diagnostics (BOM:540788), the current Days Inventory is 39.83 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aspira Pathlab & Diagnostics (BOM:540788) Overvalued in 2026?
Based on GuruFocus' analysis, Aspira Pathlab & Diagnostics stock appears to be overvalued.
The current stock price of ₹106.90 is trading 51.1% above its estimated GF Value™ of ₹70.73.
GuruFocus considers Aspira Pathlab & Diagnostics to be Significantly Overvalued.
Key valuation signals for BOM:540788:
Days Inventory: 39.83 (10% below median its 10-year median of 44.35)
GF Value™: ₹70.73 vs. price of ₹106.90 (51.1% above fair value)
Industry Position: 40.5% below the Medical Diagnostics & Research median (#53 of 178)
No single metric tells the full story. See the BOM:540788 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aspira Pathlab & Diagnostics Ltd is mainly engaged in pathology and related healthcare services. It operates laboratories that conduct a wide range of pathological investigations across branches such as biochemistry, hematology, histopathology, microbiology, immunochemistry, immunology, virology, cytology, and other pathological and radiological tests. The services offered include pathology tests, sonography, X-rays, and radiology. The company also provides various health packages like gynecology profiles, anemia profiles, monsoon profiles, coagulation tests, cancer screening packages, newborn screening and IEM panels, orthopedic profiles, allergy panels, and cardiac profiles. These comprehensive diagnostic services assist in disease diagnosis.
51GF Score
Get the complete analysis for BOM:540788
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:540788 has been successfully added to your 
